MX2013003238A - Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. - Google Patents
Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.Info
- Publication number
- MX2013003238A MX2013003238A MX2013003238A MX2013003238A MX2013003238A MX 2013003238 A MX2013003238 A MX 2013003238A MX 2013003238 A MX2013003238 A MX 2013003238A MX 2013003238 A MX2013003238 A MX 2013003238A MX 2013003238 A MX2013003238 A MX 2013003238A
- Authority
- MX
- Mexico
- Prior art keywords
- recombinant adenovirus
- malaria
- boosting composition
- subject
- adenovirus vector
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
- C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La invención provee métodos para inducir una respuesta inmunológica en un sujeto contra un antígeno de un parásito causante de malaria, preferiblemente P. falciparum, el método comprende: (i) administrar a un sujeto una composición de sensibilización que comprende antígeno proteináceo con adyuvante que comprende proteína de circumsporozoito (CS) o una parte inmunogénica. de la misma de un parásito causante de malaria; (ii) administrar al sujeto una primera composición de refuerzo que comprende un vector de adenovirus recombinante que comprende ácido nucleico que codifica proteína de CS o una parte inmunogénica de la misma de un parásito causante de malaria; y (iii) administrar al sujeto una segunda composición de refuerzo que comprende un vector de adenovirus recombinante que comprende ácido nucleico que codifica proteína de CS o una parte inmunogénica de la misma de un parásito causante de malaria, en donde ya sea la primera composición de refuerzo comprende vector de adenovirus recombinante de serotipo 35 (Ad35) y la segunda composición de refuerzo comprende un adenovirus recombinante de Ad26, o en donde la primera composición de refuerzo comprende un vector de adenovirus recombinante de Ad26 y la segunda composición de refuerzo comprende un adenovirus recombinante de Ad35.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40415610P | 2010-09-27 | 2010-09-27 | |
EP10180251 | 2010-09-27 | ||
PCT/EP2011/065434 WO2012041669A1 (en) | 2010-09-27 | 2011-09-07 | Heterologous prime boost vaccination regimen against malaria |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013003238A true MX2013003238A (es) | 2013-05-30 |
MX354752B MX354752B (es) | 2018-03-20 |
Family
ID=43416881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013003238A MX354752B (es) | 2010-09-27 | 2011-09-07 | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. |
Country Status (6)
Country | Link |
---|---|
US (1) | US9168292B2 (es) |
AU (1) | AU2011310838B2 (es) |
BR (1) | BR112013004582A2 (es) |
CA (1) | CA2809463C (es) |
MX (1) | MX354752B (es) |
WO (1) | WO2012041669A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2014CN04742A (es) | 2011-11-28 | 2015-09-18 | Crucell Holland Bv | |
EP3486256A3 (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
CN109803676A (zh) * | 2016-04-12 | 2019-05-24 | 牛津大学创新有限公司 | 初免靶向 |
CA3133971A1 (en) * | 2019-03-20 | 2020-09-24 | Turnstone Biologics Inc. | Sequential heterologous boost oncolytic viral mmunotherapy |
EP4021470A4 (en) * | 2019-08-27 | 2023-09-20 | Turnstone Biologics Corp. | METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST NEOANTIGENS |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
KR100251505B1 (ko) | 1991-11-16 | 2000-05-01 | 장 스테판느 | 말라리아원충으로부터의 cs 및 hbsag 사이의 혼성 단백질(hybrid protein between cs from plasmodium and hbsag) |
CA2085827C (en) | 1991-12-23 | 2003-10-14 | Lucas A. T. Hilgers | Adjuvant composition containing synthetic hydrophobic lipopolysaccharide |
KR100278157B1 (ko) | 1992-06-25 | 2001-01-15 | 장 스테판느 | 보조약을 함유하는 백신 조성물 |
FR2697022B1 (fr) * | 1992-10-19 | 1994-12-16 | Pasteur Institut | Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination. |
DK0812593T4 (da) | 1993-03-23 | 2008-05-13 | Smithkline Beecham Biolog | Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
SK281944B6 (sk) | 1993-11-17 | 2001-09-11 | Laboratoires Om S. A. | Beta(1->6)glukozamínové disacharidy, spôsob ich prípravy, farmaceutický prostriedok, ktorý ich obsahuje, a ich použitie |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
ATE336587T1 (de) | 1994-06-10 | 2006-09-15 | Genvec Inc | Adenoviren-vektor systeme und zelllinien |
EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
GB9620795D0 (en) | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
SI0833934T2 (sl) | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
GB9616351D0 (en) | 1996-08-02 | 1996-09-11 | Smithkline Beecham Biolog | Vaccine composition |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
EP0968284B1 (en) | 1996-11-20 | 2006-12-13 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
US6005009A (en) | 1997-03-19 | 1999-12-21 | Duke University | Method of inhibiting fibrosis with pyridoxal benzoyl hydrazone and analogs thereof |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
ES2327693T3 (es) | 1997-08-29 | 2009-11-02 | Antigenics Inc. | Composiciones que comprenden el adyvante qs-21 y polisorbato o ciclodextrina excipiente. |
WO1999011241A1 (en) | 1997-09-05 | 1999-03-11 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
ID28298A (id) | 1998-02-17 | 2001-05-10 | Schering Corp | Komposisi yang mengandung virus dan metode untuk memekatkan preparat-preparat virus |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
ATE421337T1 (de) | 1998-11-16 | 2009-02-15 | Introgen Therapeutics Inc | Adenovirus-formulierungen zur gentherapie |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
ATE519854T1 (de) | 1999-05-17 | 2011-08-15 | Crucell Holland Bv | Rekombinantes adenovirus auf basis von serotyp 48 (ad48). |
WO2001066137A1 (en) | 2000-03-07 | 2001-09-13 | Merck & Co., Inc. | Adenovirus formulations |
JP2005517394A (ja) | 2001-12-12 | 2005-06-16 | エフ エイチ フォールディング アンド カンパニー リミテッド | ウイルス保存のための組成物 |
CA2469721A1 (en) | 2002-01-18 | 2003-07-31 | Schering Aktiengesellschaft | Stabilized formulations of adenovirus |
US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
CA2478508C (en) | 2002-04-25 | 2013-07-02 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
CA2477954C (en) | 2002-04-25 | 2012-07-10 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
US20040106184A1 (en) | 2002-08-28 | 2004-06-03 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
PL376792A1 (pl) * | 2002-10-23 | 2006-01-09 | Glaxosmithkline Biologicals S.A. | Sposoby szczepienia przeciwko malarii |
US20050208078A1 (en) * | 2003-11-20 | 2005-09-22 | Hoffman Stephen L | Methods for the prevention of malaria |
EP1573012B1 (en) | 2002-12-17 | 2011-11-30 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
DK1780269T3 (da) | 2004-02-23 | 2009-10-12 | Crucell Holland Bv | Virusrensningsmetoder |
PT1802336E (pt) | 2004-10-14 | 2011-11-15 | Glaxosmithkline Biolog Sa | Vacinas de dose inicial/reforço para a malária |
DE602006003420D1 (de) | 2005-04-11 | 2008-12-11 | Crucell Holland Bv | Virusreinigung mit ultrafiltration |
EP1998804B1 (en) * | 2006-03-27 | 2014-04-16 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
WO2009117134A2 (en) | 2008-03-21 | 2009-09-24 | National Institutes Of Health | Aerosolized genetic vaccines and methods of use |
KR101504392B1 (ko) | 2008-11-03 | 2015-03-19 | 크루셀 홀란드 비.브이. | 아데노바이러스 벡터의 제조방법 |
AU2011214262B2 (en) | 2010-02-15 | 2015-05-21 | Crucell Holland B.V. | Method for the production of Ad26 adenoviral vectors |
-
2011
- 2011-09-07 BR BR112013004582A patent/BR112013004582A2/pt not_active Application Discontinuation
- 2011-09-07 US US13/823,581 patent/US9168292B2/en not_active Expired - Fee Related
- 2011-09-07 AU AU2011310838A patent/AU2011310838B2/en not_active Ceased
- 2011-09-07 CA CA2809463A patent/CA2809463C/en not_active Expired - Fee Related
- 2011-09-07 MX MX2013003238A patent/MX354752B/es active IP Right Grant
- 2011-09-07 WO PCT/EP2011/065434 patent/WO2012041669A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
BR112013004582A2 (pt) | 2016-09-06 |
WO2012041669A1 (en) | 2012-04-05 |
CA2809463C (en) | 2021-05-25 |
AU2011310838B2 (en) | 2015-11-05 |
CA2809463A1 (en) | 2012-04-05 |
MX354752B (es) | 2018-03-20 |
AU2011310838A1 (en) | 2013-03-28 |
US9168292B2 (en) | 2015-10-27 |
US20130216580A1 (en) | 2013-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX354752B (es) | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. | |
WO2020128031A3 (en) | Rna for malaria vaccines | |
IL214460A0 (en) | Malaria prime/boost vaccines | |
WO2014018858A3 (en) | Multimeric fusion protein vaccine and immunotherapeutic | |
WO2007027860A3 (en) | Adenoviral vector-based malaria vaccines | |
EA200901060A1 (ru) | Новый способ и композиции | |
MX2009010870A (es) | Vector adenoviral que codifica el antigeno de malaria. | |
SG156535A1 (en) | Recombinant viral-based malaria vaccines | |
MX360415B (es) | Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos. | |
EP4056198A3 (en) | Outer membrane vesicles | |
WO2009025770A3 (en) | A heterologous prime-boost immunization regimen | |
CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
WO2012047679A8 (en) | Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria | |
PH12015500308A1 (en) | Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same | |
EA201290675A1 (ru) | Вакцинные векторы и способы усиления иммунных ответов | |
MX2014011713A (es) | Composiciones y procedimientos antipaludismo. | |
WO2008086386A8 (en) | Adenoviral vector-based malaria vaccines | |
EA201171347A1 (ru) | Комбинированная вакцина против кори и малярии | |
WO2015070207A3 (en) | Ama-1 epitopes, antibodies, compositions, and methods of making and using the same | |
EP2451478A4 (en) | PLASMODIUM FALCIPARUM SPOROZOITE AND LIVERPHASE ANTIGENS THEREWITH | |
PL391384A1 (pl) | Kompleks rybosomalnych białek P z zarodźca malarii Plasmodium falciparum jako antygen patogenu malarii oraz sposób otrzymania tego antygenu i kaseta ekspresyjna, zwłaszcza do tego sposobu | |
WO2010127420A9 (pt) | Sequências geneticamente modificadas de antígenos de plasmodium vivax | |
WO2008027414A3 (en) | Novel p. falciparum vaccine proteins and coding sequences | |
Radošević et al. | The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |